Search

Your search keyword '"Vellenga E."' showing total 1,509 results

Search Constraints

Start Over You searched for: Author "Vellenga E." Remove constraint Author: "Vellenga E."
1,509 results on '"Vellenga E."'

Search Results

1. Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial

2. Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes:the HOVON89 trial

4. Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study

5. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio

12. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years

14. Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

22. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

23. Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with aml and high risk mds

24. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition).

25. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1.

26. Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation

27. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

28. Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with aml and high risk mds

31. Targeted RNA sequencing enables detection of relevant translocations, single nucleotide variants and automatic leukemia classification

37. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

38. Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0)

40. Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols

42. Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study

44. Achtergronden bij de richtlijn voor de behandeling van chronische myeloïde leukemie anno 2018 : Diagnostiek, behandeling en bijwerkingenmanagement

Catalog

Books, media, physical & digital resources